Hot Investor Mandate: Venture Arm of Large Drug Development Organization Supports Drug Discovery Companies With Seed and Later-Stage Investments 

2 Jun

A corporate venture capital investor headquartered in Asia is an investment arm of a large drug development organization. The firm invests globally across all stages, from Seed through later-stage financings. In addition to providing capital, the firm offers strategic and operational support spanning drug development, regulatory planning, partnering, and commercialization. The firm leverages the broader capabilities and infrastructure of its affiliated organization to help portfolio companies accelerate growth and value creation.  
 
The firm focuses on pharmaceuticals, biotechnology, and medical devices, with a strong emphasis on drug discovery and translational innovation. The firm seeks differentiated therapeutic and medical technology opportunities with strong scientific foundations and commercial potential. Within therapeutics, the firm is modality-agnostic and evaluates opportunities across a broad range of disease areas and development stages, from discovery through clinical development. The firm also participates in licensing, incubation, and strategic business development activities designed to advance promising healthcare technologies.  
 
From a company and management team perspective, the firm seeks founders and leadership teams with strong scientific expertise, differentiated intellectual property, and credible development strategies. The firm prioritizes opportunities supported by high-quality translational science and works closely with management teams to provide development resources, business development support, partnering opportunities, and commercialization expertise. Through its strategic network and operational capabilities, the firm helps portfolio companies accelerate development timelines and expand global market access. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

Hot Investor Mandate: Multi-Stage Healthcare Investment Firm Seeks Early Clinical Stage Therapeutics and Devices Near Regulatory Approval, Investing Up to $20M

2 Jun

A capital and private equity investor with a flexible investment mandate invests across a wide range of stages and sectors. On the venture capital side, the firm typically participates in Seed through Series B financings and is open to both leading and co-investing. Investments are generally made through special purpose vehicles, with typical allocation sizes ranging from approximately $2M to $20M. The firm primarily focuses on opportunities within the United States.  

Within healthcare and life sciences, the firm invests in therapeutics, medical devices, digital health, and diagnostics. For therapeutics, the firm prefers opportunities that are approaching clinical development or already in clinical trials. Within medical devices, the firm focuses on technologies that are nearing regulatory approval or have already obtained clearance or approval. The firm is disease-agnostic and evaluates opportunities based on the strength of the technology, clinical potential, and commercial opportunity.  

From a company and management team perspective, the firm generally prefers board representation and seeks to work closely with portfolio companies to support strategic growth and value creation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

Hot Investor Mandate: USA-Based VC Firm Focuses on Deeptech and Techbio Investments in Pre-Seed to Series A Rounds

2 Jun

A venture capital firm headquartered in the United States focuses on Pre-Seed through Series A opportunities across deeptech, life sciences, and the convergence of technology and healthcare. Backed by family offices and strategic investors across multiple regions, the firm benefits from a network of partners with entrepreneurial and life sciences expertise. The firm typically participates as a co-investor with check sizes ranging from approximately $100K to $1M. In addition to venture investing, the firm collaborates with capital partners on strategic acquisition opportunities and actively supports company formation and incubation. The firm invests globally and assists portfolio companies with expansion into emerging markets across Asia, Africa, and other regions. 

The firm takes an opportunistic approach to life sciences and deeptech investing. Key areas of interest include artificial intelligence, health technology, neuroscience, life science tools, and therapeutics. The firm is also open to orphan disease opportunities. Within therapeutics, the firm focuses on companies from the preclinical stage through Phase I clinical development. The firm seeks differentiated technologies with the potential to create meaningful scientific, clinical, or commercial impact. 

From a company and management team perspective, the firm does not impose specific requirements regarding leadership composition and does not require board representation as a condition of investment. The firm prefers to support founders through collaborative partnerships and strategic guidance while maintaining flexibility in investment structure and governance. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

Hot Investor Mandate: CVC Arm of Leading Healthcare Company Allocates Up to $10M in Growth-Stage Therapeutics and Diagnostics Companies

2 Jun

The firm is a corporate venture capital arm of a leading healthcare and diagnostics company based in Asia. The firm focuses on investing in later-stage life sciences and healthcare companies, typically from growth-stage financings through post-IPO opportunities. The firm generally makes investments below $10M per company and maintains a selective investment strategy. The firm evaluates opportunities globally and leverages the expertise, industry relationships, and commercial infrastructure of its parent organization to support portfolio companies.  

The firm primarily focuses on therapeutics and diagnostics, while remaining open to select medical device and digital health opportunities. Within therapeutics, the firm is most interested in programs ranging from mid- to late-stage clinical development through commercial-stage assets. Areas of interest include cardiovascular diseases, respiratory diseases, oncology, autoimmune disorders, urology, and central nervous system disorders. Within in vitro diagnostics, the firm is open to a broad range of technologies spanning development-stage through clinical and commercial applications.  

From a company and management team perspective, the firm seeks technologies with strong scientific foundations, clear commercial potential, and a high likelihood of successfully navigating regulatory approval pathways. As a strategic investor, the firm prioritizes opportunities that demonstrate meaningful differentiation and long-term market potential. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

Investors Presenting at RESI San Diego

2 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The Life Science Nation (LSN) team is gearing up for the highly anticipated RESI San Diego conference, bringing together investors, strategic partners, and early-stage life science innovators for a full day of insightful discussions and high-value networking during Convention Week.

This year’s panel lineup will explore some of the most important trends shaping early-stage healthcare investment and partnering, spanning pharma, medtech, diagnostics, oncology, AI, and venture financing. Attendees can expect perspectives from venture capital firms, corporate venture groups, pharmaceutical companies, strategics, and experienced healthcare investors actively evaluating emerging opportunities across the life science landscape.

As a global partnering conference focused on connecting early-stage companies with investors and strategic partners, RESI San Diego is designed to foster meaningful conversations between fundraising CEOs and active dealmakers. The panels will provide tactical insight into how investors assess opportunities, what strategic partners are looking for, and how companies can position themselves in today’s increasingly competitive fundraising environment.

Join the panelists below at RESI San Diego:

Friedemann-Janus
Friedemann Janus
Bayer		 Shiv-Krishnan
Shiv Krishnan
Daiichi Sankyo Co., Ltd.		 Eva-Dahlen
Eva Dahlén
Novo Nordisk
Yaron-Daniely
Yaron Daniely
aMoon Fund		 Claudia-Generaux
Claudia Generaux
Bristol Myers Squibb		 Lana Ghanem
Lana Ghanem
Hikma Ventures
Kit-Law
Mankit Law
GlaxoSmithKline (GSK)		 Debbie-Lin
Debbie Lin
T.Rx Capital		 Priya-Balachandran
Priya Balachandran
Life Science Angels
Andrew-Strong
Andrew Strong
Cancer Focus Fund		 Randy-Berholtz
Randy Berholtz
Mesa Verde Venture Partners		 Gunes-Bozkurt
Gunes Bozkurt
Beiersdorf
Damian-Carvajal-Ibanez
Damian Carvajal Ibanez
Debiopharm		 Nicolas-Cindric
Nicolas Cindric
Yahara Ventures		 Han-Dai
Han Dai
Viva BioInnovator
Luca-Giani
Luca Giani
Alumni Ventures		 Sam-Gussman-Toh
Sam Gussman-Toh
ARPA-H		 Ole-Henrik-Bang-Andreasen
Ole Henrik Bang Andreasen
Avant Bio
Rohit-Jain
Rohit Jain
HBS Alumni Angels of Northern California		 Ray-Jordan
Ray Jordan
Elmstead Holdings		 Mohsin-Khan
Mohsin Khan
Fortress Biotech
Cheryl-Kuai
Cheryl Kuai
Sixty Degree Capital		 Don-Lin
Don Lin
Guoqian Venture Capital Investment		 Andrew-Merken
Andrew Merken
Polsinelli PC
Ralph-Morales
Ralph Morales III
Aquillius Ventures		 Nick-Mourlas
Nick Mourlas
ReefHaven Ventures		 Mahesh-Narayanan
Mahesh Narayanan
Neuvation Ventures
Stephanie-Oestreich
Stephanie Oestreich
Myeloma Investment Fund		 Soyoung-Park
Soyoung Park
1004 Venture Partners		 Preetha-Ram
Preetha Ram
Pier 70 Ventures
Bob-Sweeney
Bob Sweeney
Global Health Impact Fund		 Divya-Yerraguntla
Divya Yerraguntla
Life Science Angels		 Chris-Yoo
Chris Yoo
Xcellerant Ventures
Register for RESI San Diego

Tags: , , , , , , , , , , , , ,

RESI Innovator’s Pitch Challenge Winner Amets Biotechnology on Advancing Gene Therapies for Rare Diseases 

2 Jun

By Caitlin Dolegowski, Program Director, LSN

In this interview, Nicholas Weber of Amets Biotechnology discusses the company’s work advancing gene therapies for rare pediatric diseases, including PFIC2, and shares insight into the future of rare disease innovation. Amets Biotechnology was recognized at RESI Europe as an Innovator’s Pitch Challenge winner for its promising next-generation gene therapy approach. 

Apply to Pitch at RESI Boston

 

Tags: , , , ,

What Investors Need to Hear: Turning Your Pitch into Investor Signal 

2 Jun

By Karen Deyo, VP of Product, Israel BD, LSN

karen-wp

When pitching to investors, companies often focus on the science and the benefit to the patient. While of course important, they are missing crucial information investors need to make a decision on whether or not to move forward. Investors are busy – the quicker they can make a decision, the better – there is no guarantee they will have the time to look further into a company after a pitch, so companies should make the best use of their attention while they have it.

How do investors make their decisions? What questions do they ask? LSN will be running a 3 webinar series that cover how investors make their decisions, how to cover that information clearly in your pitch, and how to translate that into positive signal from investors. Register for these webinars below:

June 4 | 1:00 PM ET
De-Risking, Shaping, and Micro-Investment – Sign Up

Strong science alone is rarely enough to secure funding. Rick Berenson (Anchor Node project) explores how investors evaluate early-stage risk and how to transform a scientific story into a shaped, investable asset. Learn how micro-investment acts as an early filtering mechanism, how to sequence de-risking activities, and how to rigorously prepare for investor outreach ahead of RESI San Diego.

June 11 | 1:00 PM ET
From Pitch Deck to De-Risk Deck – Sign Up

Investors look for legibility and risk reduction, not just vision. Dennis Ford (Founder & CEO, Life Science Nation) explains why traditional pitch decks fail and introduces the “de-risk deck”—a framework centered on structured evidence and strategic capital formation. Gain critical insights into investor targeting, outreach strategy, and the realities of life science fundraising timelines before RESI San Diego.

June 18 | 1:00 PM ET
Science to Signal – Sign Up

Max Braht and Karen Deyo introduce the *Science to Signal* framework, designed to help startups translate scientific merit into clear investment signals. Learn how this system aligns development strategy with risk assessment, its enterprise implementation in incubators, and join Dennis Ford (CEO, Life Science Nation) for a closing Q&A on fundraising strategy ahead of RESI San Diego.

Register for RESI San Diego

Tags: , , , , , , ,

← Older Entries